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Abstract 
 
We assessed the expression pattern and clinical relevance of BMPs and related molecules in 
multiple myeloma (MM). MM bone-marrow samples (n=32) had increased BMP4, BMP6, 
ACVR1 and ACVR2A, and decreased NOG expression compared with controls (n=15), with 
BMP6 having the highest sensitivity/specificity. Within MM bone-marrow, the source of BMPs 
was mainly CD138+ plasma-cell population, and BMP6 and ACVR1 expression correlated with 
plasma-cell percentage. Using myeloma cell lines NCI H929 and Thiel we showed that BMPs 
induced ID1, ID2 and IL6, and suppressed CDKN1A and BAX gene expression, and BAX protein 
expression. Finally, BMPs partially protected myeloma cells from bortezomib- and TRAIL-
induced apoptosis. We concluded that BMPs may be involved in MM pathophysiology and serve 
as myeloma cell biomarkers. 
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1. Introduction 
 
Multiple myeloma (MM) is at present an incurable B-lymphocyte neoplasia, characterized by 
slow proliferation of malignant-plasma cells (PC) in the bone-marrow (BM) [1-3]. Multiple anti-
apoptotic signaling mechanisms contribute to the accumulation of myeloma cells within the BM 
and account for their resistance to chemotherapy [4-6]. The most important molecules expressed 
by myeloma cells which promote their survival and proliferation are anti-apoptotic members of 
the BCL2 family and a number of growth factors, adhesion molecules and cytokines, especially 
IL6 [6-9]. Several cytokines have also been reported to inhibit myeloma cell growth in different 
culture conditions, including bone morphogenetic proteins (BMPs) [10,11]. Despite BMP pro-
apoptotic action on several myeloma cell lines and primary myeloma cells in vitro [12-14], other 
studies on different types of malignancies showed their tumor-promoting effects in vitro and in 
vivo [15-20]. Importantly, in vitro effects of BMPs need to be further investigated on human MM 
samples because primary myeloma cells in culture conditions are removed from the interactions 
with other cells within BM microenvironment which may regulate their response [7-9]. In 
addition, primary myeloma cells have poor survival and growth in culture [21], so the in vitro 
observations may not reveal the true biological role of BMPs in tumorigenesis. 
BMPs, members of the transforming growth factor- superfamily, had been originally identified 
by their bone-inducing activity but were later shown to regulate a broad spectrum of cellular 
responses including proliferation, differentiation, morphogenesis, chemotaxis and apoptosis in a 
variety of cell types, including haematopoietic cells [22-24]. Although BMPs affect bone cells 
and thus may be relevant in MM bone disease [25], we focused on direct BMP action on 
myeloma cells. BMPs exert their biological effects by signaling through both type I and II 
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serine/threonine kinase receptors and a family of intracellular signal transducers known as 
SMADs (small mothers against decapentaplegic) [22,23]. The most common BMP intracellular 
signaling pathway is through the phosphorylation of SMAD1/5/8 complex, which translocates to 
the nucleus and either alone or in combination with other non-SMAD transcription factors 
regulate the transcription of target genes [23]. One of the important direct target of SMAD1/5/8 
pathway in many cell systems is the inhibitor of DNA binding (ID) gene family [26-28]. ID genes 
encode a family of proteins that inhibit basics helix-loop-helix transcription factors to bind to 
DNA thus interrupting their regulatory role in many developmental and differentiation processes. 
ID family were initially identified to inhibit cell differentiation, but more recently shown to have 
a much wider biological role in regulation of cell-cycle progression, migration and invasiveness. 
Different studies on human tumors proved their oncogenic properties in regulating cell growth 
and proposed their causal role in malignant transformation, presumably through their deregulated 
expression caused by the perturbations in upstream signaling pathways [26-30]. 
Whereas other studies on the effects of BMPs on myeloma cells have been performed only in 
vitro, this is the first report describing the expression pattern of BMPs, receptors and related 
molecules in human MM BM samples, as well as their potential clinical relevance as myeloma 
cell markers. In addition, by using myeloma cell lines we showed that BMPs protect myeloma 
cells from apoptosis induced by anti-myeloma drug bortezomib [31] or tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) [32]. Our results collectively indicate that BMPs 
promote myeloma cell survival by inducing ID family of oncogenes and increasing the ratio 
between pro-survival and pro-apoptotic molecules. 
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2. Patients and Methods 
 
2.1. Primary myeloma sample collection 
After obtaining approval from the institutional Ethics Committee and informed consent from 
participants, we studied BM samples from 32 MM patients and 15 control subjects. Patients with 
MM were included in the study with a minimal diagnostic inclusion criterion of 10% malignant 
PC in cytologic or histologic BM specimen [33], obtained as part of the routine clinical 
examination. Patients were assessed clinically for myeloma stage and bone disease [34]. Most 
patients entered the study at diagnosis (21/32), whereas a few had already been treated and 
assessed at relapse (8/32) or remission (3/32) (Table 1). Patients were treated with different 
protocols adjusted for age and clinical status. 
Fifteen BM samples, obtained from subjects (nine men and six women) without history of cancer, 
served as a control group; with median age 54 years (range 30-78). Most of the control BM 
samples (13/15) were collected from subjects assigned for BM aspiration as healthy donors and 
two were from patients aspirated for observation (one with leukocytosis and one with 
megaloblastic anemia). No statistical difference was found for age and sex between patient and 
control group. 
BM specimens were obtained by sterile punction of the iliac crest, followed by mononuclear cell 
separation using Histopaque (Sigma-Aldrich, St Louis, MO, USA). In selected samples, PC from 
BM aspirates were purified by immuno-magnetic separation using anti-CD138 antibodies 
(Caltag, Invitrogen Ltd, Paisley, UK) conjugated to magnetic beads (Dynal, Invitrogen Ltd) with 
the purity of >90% as confirmed by flow-cytometry. 
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2.2. Cell culture 
The human myeloma cell lines NCI H929 (DSMZ cell line collection, Brunschweig, Germany) 
and Theil (a gift from Dr. K. Pulford, University of Oxford, UK) were used for in vitro 
experiments. Cells were grown in RPMI 1640 supplemented with 10% fetal calf serum (FCS) 
(Gibco, Invitrogen Ltd), 2 mM L-glutamine and 100 U/ml penicillin/streptomycin, in a 5% CO2 
at 37C. Recombinant human (rh)BMP2, rhBMP4 or rhBMP6 (all from R&D Systems, 
Abingdon, UK) were used for the cell treatment as indicated in each experiment. In some 
experiments, the soluble BMP antagonist noggin (NOG) (PeproTech, London, UK) was used to 
anatagonize BMP effect, whereas bortezomib (a gift from Millenium Pharmaceuticals, Inc., 
Cambridge, MA, USA) and TRAIL (R&D Systems) were used to induce myeloma cell death and 
apoptosis. All experiments were repeated three times and the representative data were shown. 
 
2.3. Flow-cytometric analysis 
Myeloma cell lines were analyzed by flow-cytometry using a FACCalibur and the Cell-Quest 
software (BD Biosciences, San Jose, CA, USA). For cell-cycle analyses, cells were resuspended 
in DNA staining solution (0.01 M Tris, 10 mM NaCl, 700 U/L RNAse, 7.510-5 M propidium 
iodide (PI), 0.01% Nonidet P-40) for 40 min in the dark. Viability and apoptosis were evaluated 
by annexin V/ PI staining (BD Biosciences) according to the manufacturer’s instructions. Cells 
were classified on dot-plots as dead (PI+), apoptotic (PI/annexin V+) or viable (double negative).  
 
2.4. Quantitative polymerase chain reaction amplification 
Total RNA was extracted (TriPure; Roche Mannheim, Germany) from primary MM BM samples 
or cultured myeloma cells, reversely transcribed to cDNA (MuLV Reverse Transcriptase; 
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Applied Biosystems, Foster City, CA) and amplified by quantitative (q)PCR using in an ABI 
Prism 7000 Sequence Detection system (Applied Biosystems). The following commercially 
available specific TagMan Gene Expression Assays, named by the official gene symbol [35] and 
the respective assay ID (Applied Biosystems), were used for the analyses: BMP2 
(Hs00154192_m1), BMP4 (Hs00370078_m1), BMP6, (Hs00233470_m1), BMP7 
(Hs00233477_m1), ACVR1 (Hs00153836_m1), ACVR2A (Hs00155658_m1), ACVR2B 
(Hs00609603_m1), BMPR1A (Hs01034910_g1), BMPR1B (Hs00176144_m1), BMPR2 
(Hs00176148_m1), SMAD5 (Hs01557454_m1), SMAD6 (Hs00178579_m1), BAMBI 
(Hs00180818_m1), NOG (Hs00271352_s1), ID1 (Hs00357821_g1), ID2 (Hs00747379_m1), IL6 
(Hs00174131_m1), BCL2 (Hs00153350_m1), TP53 (Hs00153349_m1), CDKN1A 
(Hs00355782_m1), BAX (Hs00180269_m1) and GAPDH (Hs99999905_m1). Each reaction was 
performed in triplicate in a 25 L reaction volume using TaqMan Gene Expression Master Mix 
(Applied Biosystems), as recommended by the manufacturer. Cycle conditions were: incubation 
at 50°C for 2 minutes and at 95°C for 10 minutes, then 40 cycles of 15 s at 95°C and 60 s at 
60°C. The relative quantities of unknown samples for the each gene were interpolated from the 
six-point dilution standard curve of the calibrator sample (BM cells or myeloma cell lines) as 
previously described [36]. To equalize samples according to the amount of input cDNA, the 
relative quantity of the target gene was normalized to GAPDH as the endogenous control. 
 
2.5. Enzime-linked immunosorbent assay 
Myeloma cells were solubilized in a lysis buffer for total proteins (1 mM EDTA, 0.5% Triton X-
100 in 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4; pH 7.2-7.4) or 
phosphorylated proteins (1 mM EDTA, 0.5% Triton X-100, 10 mM NaF, 150 mM NaCl, 20 mM 
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-glycerophosphate, 1 mM DTT; pH 7.2-7.4) containing protease inhibitors (Protease Inhibitor 
Cocktail Tablets; Roche). Total protein concentrations were determined in the supernatants of 
cell lyzates using a commercial kit (BCA protein assay; Pierce Biotechnology, Rockford, IL). 
The concentration of phospho-TP53 (P53), BAX and BCL2 protein in cellular extracts was 
determined by ELISA using commercial kits (DuoSet IC; R&D Systems) according to the 
manufacturer’s instructions. OD was determined on a microplate reader (Bio-Rad, Hercules, CA) 
set to 450 nm excitation wavelength. Protein concentration was interpolated from the seven-point 
dilution standard curve and expressed per mg total protein. 
 
2.6. Statistics 
Gene expression values between MM and control BM samples were expressed as median (range) 
and compared using non-parametric Mann-Whitey test. Values for RNA relative quantities and 
protein concentrations in cultured cell lines were expressed as meanSD and compared using 
analysis of variance (ANOVA). The receiver operating characteristic (ROC) curve analysis was 
expressed as area under curve (AUC) with its 95% confidence interval (CI) and used to determine 
the efficacy of analyzed genes to discriminate between MM and control group. Diagnostic 
efficacy for gene expression values were assessed through sensitivity and specificity at cut-off 
point. Gene expression values were correlated to clinical data using rank correlation and 
Spearman's coefficient of rank correlation rho () with its 95% CI. Statistical analysis was 
performed using MedCalc software-package (Mariakerke, Belgium). For all experiments, -level 
was set at 0.05. 
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3. Results 
 
3.1. Expression of BMPs and related molecules in human multiple myeloma bone-marrow 
samples 
Since it has been observed that BMPs modulate growth and survival of myeloma cells in vitro 
[10-14], we investigated the expression of BMPs, their receptors and intracellular molecules 
related to BMP signaling in MM BM samples. To detect changes in the whole MM BM 
microenvironment, we compared the expression of BMP2, BMP4, BMP6 and BMP7 in total 
mononuclear cell population of 32 MM BM samples (Table 1) with 15 control BM samples by 
qPCR (Table 2, Fig 1A). The expression of BMP4 and BMP6 was significantly higher in MM 
BM samples compared with control BM samples. BMP7 expression was below the detection 
limit of the qPCR assay in most samples. 
We also analyzed the expression of several molecules involved in BMP signal transduction, 
including BMP receptors – ACVR1 (ALK2), BMPR1A (ALK3), BMPR1B (ALK6), BMPR2, 
ACVR2A, ACVR2B, decoy receptor BAMBI (bone morphogenetic protein and activin membrane-
bound inhibitor), intracellular signaling molecules – activatory SMAD5 and inhibitory SMAD6, 
BMP antagonist NOG, and inhibitors of DNA binding ID1 and ID2. Significant increase in the 
expression was found for ACVR1 and ACVR2A, both binding BMP6 [22], whereas NOG 
expression was significantly down-regulated in MM BM samples compared with controls (Table 
2, Fig 1A). 
To assess their clinical importance, we further correlated the expression of different BMPs and 
corresponding receptors in MM BM samples with the clinical data. Most of the analyzed samples 
were obtained at diagnosis (21/32) or at relapse (8/32), reflecting active disease at the time of 
collection (Table 1). Significant positive correlation was found for the PC percentage in MM BM 
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samples and BMP6 expression (Fig 1B; Spearman's  = 0.56, 95% CI 0.28-0.76, p = 0.001) as 
well as ACVR1 expression (Fig 1B; Spearman's  = 0.50, 95% CI 0.15-0.73, p = 0.010). 
Interestingly, the expression of BMP6 and ACVR1 also correlated with each other (Spearman's  
= 0.43, 95% CI 0.07-0.69, p = 0.026). 
Finally, we constructed ROC curves from the qPCR data for BMPs and related molecules to 
assess the ability of gene expression values to discriminate between the MM and control BM 
samples. The ROC curve analysis revealed the potential usefulness of the gene expression values 
for BMP4, BMP6, ACVR1, ACVR2A and NOG as MM molecular markers since they differ 
significantly between MM and control BM samples (Fig 1C; p (AUC = 0.5) for presented 
molecules < 0.05). BMP6 expression showed the greatest area under ROC curve value (AUC = 
0.92, 95% CI 0.79-0.98; p (AUC = 0.5) < 0.001) and the best diagnostic efficacy as marker of 
malignant MM BM cells among tested molecules (cut-off point >1.9, sensitivity 0.89 and 
specificity 0.86). 
BMPs may be produced by several cell types within the mononuclear fraction of BM cells [22]. 
To identify the source of BMPs in MM BM samples, we analyzed the expression of BMPs and 
related molecules in purified CD138+ malignant PC population of four MM BM samples 
obtained during routine clinical assessments (MM1, MM3 and MM4 at diagnosis and MM2 at 
progression; Table 3) and compared the expression pattern between the whole mononuclear 
fraction of MM BM aspirates, CD138 and CD138+ populations (Fig 2). All samples expressed 
these molecules, albeit with high inter-individual variability (Table 3). The lowest expression was 
detected in the sample MM1, which was obtained from the patient with the most benign disease 
stage. Most of the molecules were relatively over-expressed in CD138+ PC population compared 
with the whole BM aspirate, especially BMP4, BMP6 and ID1 (Fig 2). This finding indicates that 
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PC may be the source of BMPs and offers the potential clinical usefulness of BMPs as MM PC 
biomarkers. 
 
3.2. Protection effect of BMPs on myeloma cells in vitro 
Since we found significant over-expression of several BMPs and corresponding receptors in MM 
BM samples, we tested the effects of BMPs on myeloma cells in vitro. As primary myeloma cells 
are known for their poor ability to survive and divide in culture [21], we investigated the 
mechanisms by which BMPs affect myeloma cells using myeloma cell lines. First we tested 
several myeloma cell lines (data not shown) and than used NCI H929 and Thiel cells to confirm 
the effect of BMPs on myeloma cell survival. Both MM cell lines expressed BMPs and 
corresponding receptors but to the very different extent (Fig 3). The greatest difference was found 
for BMP7, BMPR1A and ACVR2B, which were over-expressed in NCI H929 cells, whereas 
BMP4, ACVR1 and ACVR2A were over-expressed in Thiel cells. Those differences may explain 
different response of cell lines to BMP treatment, seen after addition of bortezomib and TRAIL 
(Fig 4). 
When those cells were cultures for up to 72 hours with relatively high dose of BMP2, BMP4 or 
BMP6 (0.5 g/mL for all), in our experimental setting we could not induce significant changes in 
the proportion of dead and apoptotic cells determined by annexin V/PI staining and cell-cycle 
distribution (data not shown). Nevertheless, BMPs were able to partially protect myeloma cells 
from bortezomib- and TRAIL-induced apoptosis and increase cell survival, especially of 
bortezomib treated Thiel cells at earlier culture time-points (Fig 4). 
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3.3. Intracellular effects of BMPs on myeloma cell lines 
We then analyzed the gene expression pattern of several groups of intracellular molecules, known 
to be important for myeloma cell survival, in order to determine the final effect of BMPs on 
myeloma cells, including tumor suppressor TP53 (P53) that transcriptionally regulate CDKN1A 
(P21) and BAX [10], ID oncogenes [27], anti-apoptotic BCL2 [4] and growth factor IL6 [7]. We 
used BMP2 and BMP6 since they bind to different BMP receptors, whereas BMP2 and BMP4 
overlap in receptor molecule usage [22].  
Treatment of Thiel cells with BMP2 or BMP6 (0.5 g/mL for both) for 24 hours produced weak 
effect on TP53 (data not shown), but significantly down-regulated CDKN1A and BAX, indicating 
pro-survival action (Fig 5A). The expression of IL6, an autocrine and paracrine growth factor of 
myeloma cells [7], was increased in Thiel cells with BMP6 (Fig 5A). Moreover, ID genes were 
induced by BMPs in both cell lines. Interestingly, NCI H929 cells, carrying t(4;14) translocation, 
had much higher constitutive expression of ID1, whereas Thiel plasma-blast cell line had lower 
TP53 and higher BCL2 constitutive expression (data not shown) as well as greater induction of 
ID genes by BMPs (Fig 5A). In addition, we found that BMP treatment up-regulated the 
expression of extracellular BMP antagonist NOG and inhibitory transcription factor SMAD6 
especially in Thiel cell line (Fig 5A). Similar results of gene expression in myeloma cell lines 
were observed after BMP treatment for 12 h (data not shown). In a dose response experiments, 
ID genes showed dose-dependent induction of expression by BMPs in Thiel cells (Fig 5B). 
Suppression of BMP induced gene expression of ID1 with BMP-specific soluble antagonist NOG 
(2 g/mL), confirmed that over-expression of ID genes was a specific effect of BMPs (Fig 5C). 
In addition to gene expression, we measured the concentration of phosphorylated TP53 by 
ELISA to assess the activation of transcription factor TP53 in NCI H929 and Thiel cells with 
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BMP2 or BMP6 (0.5 g/mL for both), but did not find significant effect within 12 hours upon 
treatment (data not shown). We also assessed the concentration of BCL2 and BAX, which has 
been shown to reciprocally regulate cell survival versus apoptosis [37,38]. Addition of BMP2 or 
BMP6 did not change BCL2, but significantly decreased BAX concentration within 24 hours 
upon treatment (Fig 5D). The final effect of BMP treatment was a 45% increase in the ratio of 
BCL2/BAX in Thiel cell line, indicating pro-survival effect. 
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Discussion 
 
Other studies on the effects of BMPs on myeloma cells have been performed only in vitro, 
whereas the role of BMPs in tumorigenesis is still controversial. Therefore we investigated the 
expression pattern of BMPs, receptors and related molecules in multiple myeloma (MM) bone-
marrow samples and demonstrated that BM samples from MM patients over-expressed not only 
BMP4 and BMP6 but also their receptors ACVR1 and ACVR2A, and at the same time had 
decreased expression of BMP antagonist NOG. To the best of our knowledge, this is the first 
report describing the expression pattern of BMPs, receptors and related molecules in human MM 
BM samples, as well as its clinical relevance since the ROC curve analysis demonstrated 
potential usefulness of the gene expression values as MM markers that differ from control BM 
samples, with BMP6 having the highest sensitivity and specificity. ROC curve analysis is 
considered to be more biologically and clinically relevant than simple group comparison (t-test or 
Mann-Whitney test) [39]. Moreover, once the cut-off value is defined by the ROC curve profile at 
desirable sensitivity and specificity, additional samples could be classified in respect to this cut-
off point. By the analysis of total mononuclear cell population of MM samples we confirmed 
BMP over-expression in BM microenvironment of MM compared with control samples. In 
addition, we confirmed that the source of BMP expression was predominantly CD138+ 
population. A possible mechanism of pro-survival effects of BMPs on myeloma cells was 
through targeting the ID family of oncogenes, because ID1 was over-expressed in separated 
CD138+ myeloma cells compared to whole BM aspirates of MM patients. By using mayloma cell 
lines, we demonstrated that ID1 and ID2 were induced in myeloma cells by BMPs and BMPs 
were able to partially protected myeloma cell lines from bortezomib- and TRAIL-induced 
apoptosis.  
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We believe that our finding of BMP over-expression in primary MM BM samples provides 
strong evidence that BMPs may have a true biological role in tumorigenesis. BMP6 seems to be 
specifically important for MM, since the expression of both BMP6 and its receptors was higher in 
MM BM samples compared with controls, and BMP6 and ACVR1 correlated with the percentage 
of PC in MM BM samples. Moreover, BMP6 was relatively over-expressed in purified CD138+ 
MM PC population compared to CD138 cells. Several studies on global gene expression 
profiling observed up-regulation of some BMPs or related molecules in myeloma cells from 
human samples or myeloma cell lines [40-42]. Therefore we were interested to explore direct 
effects of BMPs on myeloma cells, aside from the effects on bone cells [25]. The proposed 
tumor-promoting role of BMPs is in line with the findings of increased BMP activity in other 
types of hematopoietic malignancies such as acute promyelocytic leukemia [43,44]. Over-
expression of BMPs correlates with unfavorable prognosis in melanoma [20], non-small-cell lung 
carcinoma [18] and diffuse large-B-cell lymphoma [19]. In addition, several BMPs have the 
ability to promote proliferation in various carcinoma cell lines, including lung [45], breast [15], 
colon [16] and prostate [17]. 
However, our findings on myeloma cell lines in vitro differ from previous observations that 
several BMPs inhibit proliferation and induce apoptosis in myeloma cell lines and separated 
CD138+ primary cells in vitro [10-14]. The inconsistency of BMP effects on myeloma cells may 
be at least partially explained by specific culture conditions, since the action of BMPs in vitro 
depends on the local environment. BMPs signal through several intracellular pathways, including 
phosphorylation of AHSA1 (P38), STAT3 and SMAD1/5/8 [23], which are not equally activated 
in different culture conditions. For example, BMP2 stimulate proliferation of lung cancer cells 
when cultured in medium containing serum compared with serum-free medium, in a way 
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dependent on the activation of SMAD1/5 and over-expression of BMP target gene ID1 [45]. 
Moreover, different myeloma cell lines and primary samples are genetically and biologically very 
heterogeneous [21,45,46] and, probably therefore, response differently to BMPs. We showed that 
plasma-blast Thiel cells were more sensitive to BMP protective effect after treatment with 
bortezomib compared with NCI H929 cells and at the same time greatly differ in the expression 
of BMPs, their receptors and down-stream signaling molecules. In addition, BMPs stimulate the 
expression of their own antagonists, as we demonstrated for NOG and SMAD6, which may limit 
the duration of BMP activity in culture [47].  
BMPs, like other growth factors, may affect the expression of a number of genes associated with 
apoptosis but also with cell-cycle progression, including oncogenes of ID family [22,26,37]. Our 
study on cell lines demonstrated that BMPs induced ID1 and ID2 gene expression, especially in 
Thiel plasma-blast cells, whereas NCI H929 cells, carrying unfavorable t(4;14) translocation, 
exhibited higher constitutive expression of ID1. In MM BM primary samples, the major source of 
ID1 expression was CD138+ population. Over-expression of ID1 was observed in a variety of 
human malignancies including MM, in which ID1 expression was associated with the t(4;14) 
translocation that indicates poor prognosis [48]. Since ID1 enhanced proliferation and stimulated 
the invasiveness of several cancer cell types [29,30], it seems likely that malignant transformation 
reactivates proliferative machinery, temporarily inhibited in normal differentiated cells, through 
enhanced expression of ID genes [26].  
The unique effect of BMPs on myeloma cell lines, observed in our experimental setting, may be 
explained by the susceptibility of treated myeloma cells, determined by their intrinsic balance 
between pro-survival and pro-apoptotic factors. Induction of ID genes by BMPs was paralleled 
by the suppression of pro-apoptotic factors BAX and CDKN1A. Moreover, BMP treatment 
increased BCL2/BAX protein ratio, which has been recognized as a key indicator of suppressed 
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apoptosis [37]. IL6, which promotes growth of myeloma cells and counteracts apoptotic signals 
by regulating BCL2 family [49], was enhanced by BMP treatment in our conditions. It is known 
that resistance to apoptosis, common in myeloma cells, depends on activated intracellular 
pathways in the particular circumstances and constitutive expression of molecules acting at cell-
cycle checkpoints [6-9,23]. Relatively high basal apoptotic rate and the slow division of myeloma 
cells in culture may explain why BMPs exhibited the protective role on myeloma cell lines only 
in conditions of bortezomib- or TRAIL-induced apoptosis. 
 
Conclusions 
In the context of their role in myeloma cell survival versus apoptosis, BMPs may initiate several 
intracellular signaling pathways. Using myeloma cell lines, we demonstrated that BMP treatment 
up-regulated pro-survival ID1, ID2 and IL6, whereas down-regulated pro-apoptotic CDKN1A and 
BAX genes as well as suppressed bortezomib- and TRAIL-induced myeloma cell apoptosis. In 
addition, in primary MM BM samples BMP6 and ACVR1 expression significantly correlated with 
the percentage of PC and purified CD138+ PC expressed BMPs and BMP receptors, suggesting 
that the biological effect of BMPs in vivo may be to promote survival and accumulation of 
myeloma cells within the BM by an autocrine action. We also proposed that BMPs may be of 
clinical relevance in MM, since they were over-expressed in MM BM and discriminated between 
control and MM samples by ROC curve analysis. Further studies should address the molecular 
mechanisms of cell sensitivity to BMPs and regulation of BMP expression by clinical treatment 
of MM. Our findings also indicated that the final effect of cell-cycle regulators, as a novel anti-
myeloma therapeutic strategy, may vary depending of the individual biological characteristics of 
myeloma cells. 
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Table 1. Clinical characteristics of patients with multiple myeloma 
Clinical feature No. of patients (n=32) 
Sex (male/female) 17/15 
Age (years) median (range) 63 (46-86) 
Type of sample 
At diagnosis 
At relapse  
At remission 
 
21 
8 
3 
Outcome (alive/dead) 22/10 
Multiple myeloma stage1 
I 
II 
III 
 
10 (9 A and 1 B) 
7 (all A) 
15 (10 A and 5 B) 
Type of myeloma protein 
IgG 
IgA 
Bence Jones 
 
21 
4 
7 
Bone disease* 
0 
1 
2 
3 
 
10 
6 
4 
12 
1 Multiple myeloma was clinically staged according to Durie–Salmon system and bone disease. 
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Table 2. Expression of bone morphogenetic proteins and related molecules in multiple myeloma 
bone-marrow samples compared with bone-marrow from control subjects 
Gene1 MM samples2 
median (range) 
Control samples 
median (range) 
P3 
(Mann-Whitney) 
BMPs    
BMP2 0.57 (0-7.03) 0.84 (0.14-9.43) 0.080 
BMP4 9.34 (0.20-406.00) 0.85 (0-11.90) 0.002 
BMP6 43.56 (0.39-519.45) 0.94 (0-5.87) <0.001 
BMP receptors    
ACVR1 1.75 (0.42-11.00) 0.97 (0-2.51) 0.011 
BMPR1A 1.47 (0.12-28.80) 0.62 (0.10-9.16) 0.090 
BMPR1B 0.08 (0-13.90) 0.26 (0-2.30) 0.880 
BMPR2 0.95 (0.19-3.63) 0.82 (0.11-2.74) 0.149 
ACVR2A 0.25 (0.03-6.35) 0.13 (0-0.78) 0.032 
ACVR2B 0.14 (0.01-1.84) 0.08 (0.01-1.30) 0.263 
Related molecules    
ID1 0.23 (0-1.64) 0.12 (0.03-0.89) 0.402 
ID2 1.29 (0.21-7.61) 1.44 (0.24-3.62) 0.461 
NOG 1.04 (0-37.72) 12.43 (1.25-69.99) <0.001 
SMAD5 0.73 (0.11-11.10) 0.49 (0.10-9.80) 0.341 
SMAD6 0.22 (0-2.16) 0.29 (0-0.70) 0.747 
BAMBI 1.79 (0-83.22) 2.09 (0.91-20.56) 0.379 
1 Gene expression was calculated as RNA relative quantity for target gene and normalized to the 
expression of GAPDH. BMP, bone morphogenetic protein; BMPR, BMP receptor; ACVR, activin 
receptor; ID, inhibitor of DNA binding; NOG, BMP antagonist noggin; SMAD, small mothers 
against decapentaplegic; BAMBI, bone morphogenetic protein and activin membrane-bound 
inhibitor. BMP7 expression was below the detection limit of the qPCR assay in most samples. 
2 Primary samples were obtained after the informed consent from patient with multiple myeloma 
(MM) and control subjects that were clinically observed for other reasons. 
3 Comparisons with statistically significant difference (p<0.05) are bolded. 
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Table 3. Gene expression analysis of bone morphogenetic proteins and related molecules in 
purified CD138+ bone-marrow cells of selected multiple myeloma bone-marrow samples 
Sample MM1 MM2 MM3 MM4 
Patient characteristics1     
Gender/age F/53 F/57 M/64 F/86 
Type of M protein IgG BJ IgA IgG 
Stage 1A 2A 2A 3B 
Bone disease 0 0 1 1 
Percent of plasma-cells 12 30 30 85 
Translocation t(4;14)   +  
Serum albumin (g/L) 43 48 45 29 
2-microglobulin (mg/L) 4.3 6.0 2.5 9.8 
Gene expression2     
BMP2 0.38 0.69 0.97 1.12 
BMP4 0.51 22.02 313.22 42.40 
BMP6 5.56 102.89 64.37 52.82 
ACVR1 0.88 5.42 2.03 1.68 
BMPR1A 0.05 0.83 0.29 1.37 
ACVR2A 0.42 1.12 2.98 4.76 
ID1 0.12 4.64 2.28 3.06 
ID2 1.81 1.04 1.96 1.88 
1 Four primary myeloma samples were obtained from patients during routine clinical assessment 
(MM1, MM3 and MM4 at diagnosis and MM2 at progression). Multiple myeloma was clinically 
staged according to Durie–Salmon system and bone disease. F, female; M, male; BJ, Bence 
Jones. 
2 Gene expression in CD138+ fraction of myeloma bone-marrow aspirates were analyzed by RT-
qPCR. Gene expression was calculated as RNA relative quantity for target gene and normalized 
to the expression of GAPDH. BMP, bone morphogenetic protein; BMPR, BMP receptor; ACVR, 
activin receptor; ID, inhibitor of DNA binding.  
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Figure legends 
 
Figure 1. Gene expression of bone morphogenetic proteins (BMPs) and related molecules in 
bone-marrow (BM) samples of patients with multiple myeloma (MM) compared with BM 
obtained from control subjects. A) Expression of BMP4, BMP6, BMP receptors activin receptor 
(ACVR)1 and ACVR2A, and BMP antagonist noggin (NOG) in MM BM samples (n=32) 
compared with control samples (n=15); lines indicate median value. B) Correlation of BMP6 and 
ACVR1 expression and the percentage of plasma-cells in MM BM samples. , Spearman's 
coefficient of rank correlation. C) Receiver operating characteristic curve profiles for the 
expression of BMP4, BMP6, ACVR1, ACVR2A and NOG. p, indicates discriminative ability of 
gene expression values between MM and control samples. 
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Figure 2. Expression of bone morphogenetic proteins (BMPs) and related molecules in purified 
multiple myeloma (MM) bone-marrow (BM) samples. The whole MM BM aspirates of four 
patients obtained during routine clinical assessment (MM1, MM3 and MM4 at diagnosis, and 
MM2 at progression) were separated using magnetic beads conjugated to anti-CD138 antibodies. 
RNA, extracted from the whole aspirates and separated fractions – CD138 and CD138+, were 
analyzed by RT-qPCR. Expression of target genes activin receptor (ACVR)1, ACVR2A, BMP4, 
BMP6, and inhibitor of DNA binding ID1 was presented as RNA relative quantity and 
normalized to the expression of GAPDH. 
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Figure 3. Expression of bone morphogenetic proteins (BMPs) and corresponding receptors in 
myeloma cell lines – NCI H929 and Thiel. RNA was extracted from myeloma cells end analyzed 
by RT-qPCR. Expression of target genes BMP2, BMP4, BMP6, BMP7, activin receptor 
(ACVR)1, BMP receptor (BMPR)1A, BMPR1B, BMPR2, ACVR2A, and ACVR2B was presented 
as RNA relative quantity (meanSD) and normalized to the expression of GAPDH. 
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Figure 4. Flow-cytometric analysis of myeloma cell lines treated with bone morphogenetic 
proteins (BMPs) in combination with bortezomib (Bort) or tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL). Two myeloma cell lines NCI H929 and Thiel were treated 
with Bort (4 nM or 5.2 nM respectively) or TRAIL (200 ng/mL or 800 ng/mL respectively). In 
some groups, myeloma cells were also treated with BMP2, BMP4 or BMP6 (0.5 g/mL for all) 
and culture for up to 72 hours. A) Representative plots for the determination of the percentage of 
death/apoptotic cells by annexin V/propidium iodide (PI) staining in Thiel cells harvested 72 
hours after the combined treatment with BMP6 and Bort. B) Percentage of annexin V positive 
cells in two myeloma cell lines, NCI H929 (left panel) and Thiel (right panel) after the combined 
treatment with BMPs and Bort (upper panel) or TRAIL (lower panel). Cells treated only with 
BMPs respond similarly as non-treated controls (not shown). Data are the representative of three 
similar experiments. 
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Figure 5. Intracellular effects of bone morphogenetic protein (BMP) treatment on myeloma cell 
lines NCI H929 and Thiel. Expression of target gene normalized to the expression of GAPDH 
was presented as RNA relative quantity (meanSD). A) Myeloma cells were treated with BMP2 
or BMP6 (0.5 g/mL for both) for 24 hours and analyzed for the expression of pro-apoptotic 
molecules CDKN1A and BAX, autocrine myeloma growth factor IL6, inhibitors of DNA binding 
ID1 and ID2, BMP antagonist noggin (NOG) and intracellular inhibitor SMAD6. Statistically 
significant differences for the expression of CDKN1A, BAX, IL6, ID2 and NOG in Thiel cells, 
and for ID1 and SMAD6 for both cell lines were found between control and BMP-treated groups 
(p<0.05, ANOVA). B) Several doses of BMP2 and BMP6 were applied for 24 hours to test a 
dose response effect on the expression of selected molecules in myeloma cell lines. C) 
Suppression of BMP effect by noggin after 24 hour treatment was assessed by ID1 gene 
expression in myeloma cell lines. Statistically significant difference for the ID1 expression was 
found between the corresponding groups without and with addition of noggin (p<0.05, ANOVA). 
D) Concentration of BAX and BCL2 protein was determined in myeloma cells after the treatment 
with BMP2 or BMP6 (0.5 g/mL for both) for up to 24 hours. Protein concentration was 
determined in cellular protein extracts by ELISA. Amount of target proteins (meanSD) were 
expressed relatively to the total protein cellular content. Statistically significant difference for 
BAX concentration was found between control and BMP-treated groups for the time-point of 24 
hours (p<0.05, ANOVA). Data are the representative of three similar experiments. 
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